Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2015: Financial Incentives Did Not Improve Linkage to Care or HIV Viral Suppression

A U.S. study that offered patients gift cards to present for HIV care after testing, and also to stay in care and maintain an undetectable viral load, did not succeed in its main aims and with most patients. Rates of linkage to care, retention in care, and viral suppression were not significantly higher in centers where patients received gift cards than in ones where they did not, according to research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. However, the study did produce some improvement in the proportion of people who remained in care. And it improved viral suppression rates in smaller and under-performing centers.

alt

Read more:

CROI 2015: Antiretroviral Therapy -- Past, Present and Future [VIDEO]

Antiretroviral therapy (ART) has undergone a remarkable evolution from AZT monotherapy in the late 1980s, to effective combination therapy in the mid-1990s, to today's well-tolerated single-tablet regimens. But questions about the optimal time to start treatment remain unanswered and getting ART to everyone who needs it is still a challenge, according to a presentation by David Cooper at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Treatment Cascades and Viral Load Surveys Inform ART as Prevention in Africa

Reaching ambitious HIV prevention targets in South Africa will require intensified efforts to engage and retain men and young people in care, in order to increase the proportion of people on HIV treatment with suppressed viral load, according to a national study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) last week in Seattle. Another study, conducted in 3 countries in sub-Saharan Africa, showed that to maximize the preventive effect of antiretroviral therapy (ART), efforts to expand treatment coverage need to focus on those with the highest viral load off treatment -- mainly people who are already eligible for treatment under current guidelines.

alt

Read more:

CROI 2015: Antiretrovirals in the Pipeline: New Tenofovir and HIV Maturation Inhibitor [VIDEO]

Tenofovir alafenamide, a new formulation that works as well as the current formulation but is easier on the kidneys and bones, and BMS-955176, a maturation inhibitor that prevents HIV from producing complete new infectious virus, were among the novel antiretroviral drugs discussed at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle.

alt

Read more:

Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.

HIVandHepatitis.com coverage by topic

CROI website

3/2/15

alt

CROI 2015: HIV Attachment Inhibitor BMS-663068 Shown Safe and Effective in Phase 2b Study

Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Related research showed that BMS-663068 can safely be taken with antiretrovirals commonly used by treatment-experienced patients. A Phase 3 trial is now underway.

alt

Read more:

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.

alt

Read more: